Browse the corpus

Jessner lymphocytic infiltration of the skin (JLIS) is a rare, benign, and recurrent dermatologic condition characterized by non-scaly erythematous papules and plaques that most commonly affect sun-exposed areas such as the face, neck, and trunk. The disorder follows an indolent course, often resolving spontaneously but frequently recurring at the same or previously unaffected sites. Histopathologic evaluation demonstrates dense, superficial and deep, perivascular and periadnexal CD8+ T-cell–predominant infiltrates, with clusters of plasmacytoid dendritic cells in the dermis. Although the etiology remains unclear, proposed mechanisms include photosensitivity, autoimmune associations, genetic predisposition, and medication triggers. There is ongoing debate over whether JLIS constitutes a distinct entity or is part of a broader spectrum of cutaneous lymphoproliferative or lupus-related disorders. This activity reviews the epidemiology, pathophysiology, clinical presentation, histopathology, diagnostic evaluation, and differential diagnosis of JLIS, with emphasis on distinguishing it from lupus erythematosus, polymorphous light eruption, and cutaneous lymphoma. This activity also provides healthcare professionals with the knowledge to perform appropriate diagnostic workups, implement evidence-based management strategies, coordinate interprofessional care, and counsel patients regarding prognosis and recurrence. Objectives: Identify key histopathologic features that distinguish Jessner lymphocytic infiltration of the skin from cutaneous lupus erythematosus and cutaneous lymphoma. Evaluate patients with suspected Jessner lymphocytic infiltration of the skin through appropriate history, physical examination, and biopsy-based diagnostic workup. Select appropriate therapeutic options based on lesion severity, patient preference, and safety profile. Communicate diagnostic findings and management plans effectively among members of the interprofessional team to ensure accurate identification of Jessner lymphocytic infiltration of the skin and avoid misdiagnosis. Access free multiple choice questions on this topic.

Jessner lymphocytic infiltration of the skin (JLIS) is a rare, benign cutaneous condition characterized by papular or plaque-like eruptions that typically involve sun-exposed areas, such as the face, neck, and trunk.[1] The eruptions are erythematous, non-scaly, and may also be annular. This disease has an indolent course, lasting weeks to months, and as the eruptions expand peripherally, they can sometimes exhibit central clearing or healing. The eruptions may resolve spontaneously or with medication, without sequelae, but they frequently recur. The lesions are typically asymptomatic, but some patients may experience burning sensations and pruritus. JLIS is diagnosed by biopsy, which reveals perivascular and periadnexal clusters of plasmacytoid monocytes within the dermis, occasionally extending into the subcutaneous tissue. These cells, also known as plasmacytoid dendritic cells, are integral to the induction of autoimmune diseases and other dermatological conditions.[2] Although their presence, combined with an inappropriate CD8+ T-cell–predominant lymphoid infiltrate, provides a definitive diagnosis of JLIS, the etiology of this disorder remains unknown. Nonetheless, there exists a potential for hereditary and autoimmune components. JLIS, also recognized as benign lymphocytic infiltration of the skin, Jessner-Kanof syndrome, and benign chronic T-cell infiltrative disease, was first documented in 1953 by Max Jessner and Norman Kanof. JLIS was previously classified under the overarching term "cutaneous lymphoid hyperplasia," which also encompassed lymphocytoma cutis and malignant lymphomas, all of which are skin conditions characterized by lymphocytic infiltrates. There remains debate regarding whether this disease constitutes a distinct entity or is part of a spectrum of cutaneous disorders, including discoid lupus erythematosus, polymorphous light eruption (PLE), and potentially malignant lymphoma.[3][4][5][6][7][8][9] Nonetheless, there is no definitive evidence indicating progression to any of the aforementioned conditions; however, case reports have documented patients with concurrent manifestations.[4]

The etiology of JLIS remains unknown, but numerous potential etiologies have been proposed. There may be a genetic component, as multiple familial cases of the disease have been reported.[10] Another possible etiology is autoimmunity. The presence of plasmacytoid dendritic cells in JLIS may suggest an autoimmune etiology, such as systemic lupus erythematosus (SLE).[2]  One hypothesis is that JLIS may be an early cutaneous manifestation of SLE or even a progression of lupus erythematosus timidus.[1][2][3][6] These hypotheses are substantiated by the dermal manifestations of JLIS, erythema multiforme, tinea versicolor, and cutaneous lymphoma observed in patients with anti-HMGCR antibody-positive myopathy (HMGCR-IMNM).[11][12] Suppression of natural killer cell cytolytic activity suggests altered immunoregulatory pathways, similar to those in neoplastic and endocrine disorders. Further studies report that photosensitivity is a trigger for JLIS, linking the disease to PLE. The typical distribution of eruptions in sun-exposed areas further supports this possible etiology. Drug-induced cases have also been reported, primarily associated with angiotensin-converting enzyme inhibitors and immunosuppressive therapies such as etanercept, ustekinumab, leflunomide, and glatiramer acetate.[13][14][15] Less commonly reported triggers include duloxetine, HIV, and Borrelia burgdorferi infection.[16]

JLIS is an uncommon condition with unknown incidence and prevalence in the United States and worldwide. The onset of JLIS typically occurs in individuals aged between 30 and 50; however, cases have also been reported in children, albeit less frequently.[17] Although JLIS was initially believed to be more prevalent among males, recent studies indicate no gender bias, and there is no evidence suggesting racial predominance.

JLIS was historically regarded as a CD8+ polyclonal reactive skin disorder. The pathophysiology remains largely unknown; however, the prevailing hypothesis involves plasmacytoid dendritic cell–mediated migration of lymphocytes, resulting in an aberrant accumulation of CD8+ T lymphocytes within the dermis. The etiology of the formation of clusters of plasmacytoid dendritic cells in the affected perivascular and periadnexal regions is yet to be elucidated.

Histopathological examination of skin biopsies reveals a normal epidermis without atrophy, follicular plugging, basal vacuolar change, or basement membrane thickening. There are dense superficial and deep perivascular and periadnexal CD8+ T-cell lymphocytic infiltrates within the dermis that sometimes extend into the subcutaneous tissue and can also be perifollicular (see Image. Inflammatory Infiltrate in Jessner's Dermatitis, Mostly of Small Mature Lymphocytes). T cells are typically located more peripherally, whereas B cells expressing follicular center differentiation are found near superficial vessels.[18][19] Perivascular and periadnexal clusters of plasmacytoid monocytes are also present within the dermis.[2] Plasmacytoid monocytes, also known as plasmacytoid dendritic cells, are larger than lymphocytes with a pale nucleus and a relatively large single nucleolus. These cells are typically scattered throughout the dermis. During active eruptions, circulating immune complex levels increase, but they generally return to normal as the eruption resolves. In addition, natural killer cell cytolytic function is often depressed.[20]

Patients with JLIS typically report asymptomatic, non-scaly, erythematous, solitary or multiple plaques or papules in sun-exposed regions, such as the face, neck, and trunk, persisting for weeks to months.[1] The history may reveal the onset or aggravation of these lesions following sun exposure. The lesions may resolve spontaneously without sequelae and subsequently recur at the same or at previously unaffected sites. Although lesions are generally asymptomatic, some patients may experience burning sensations or pruritus. Given that some case reports suggest a hereditary pattern, a comprehensive history should include inquiry into similar lesions in family members. Additionally, given the suspected autoimmune component, both personal and family histories of autoimmune disease should be evaluated.[5] On physical examination, lesions are well demarcated and may appear annular or demonstrate peripheral expansion. The surface is non-scaly, showing no evidence of follicular plugging or atrophy. Lesions are typically arranged in crescent-shaped rings, ranging from 2 mm to 2 cm in diameter. A meticulous skin examination is essential because multiple lesions may be present. Commonly affected areas include the malar region of the face and the upper back; however, lesions may also occur on other parts of the body, including the forehead, neck, mastoid region, arms, legs, and trunk.

Basic laboratory investigations, including a complete blood count and urinalysis, are recommended. Autoimmune Workup The initial evaluation should include antinuclear antibody (ANA) testing and an erythrocyte sedimentation rate. If results are positive, further assessment for SLE is recommended, including anti-Smith (anti-Sm) and anti–double-stranded DNA (anti-dsDNA) antibodies. Testing for antiphospholipid syndrome should include lupus anticoagulant, anti-cardiolipin, and anti-apolipoprotein antibodies. Assessment for Sjögren syndrome should include anti-Ro and anti-La antibodies. Rheumatoid arthritis assessment should include rheumatoid factor and anti-citrullinated protein antibodies. Evaluation for anti-HMGCR myopathy should include anti-HMGCR antibody testing (antibodies against HMG-CoA reductase), creatine kinase measurement, and liver enzyme testing.[12] Additional Tests UVA- and UVB-provocative phototoxicity testing should be considered.[21] Diagnostic Procedures Skin biopsy with hematoxylin and eosin staining, direct immunofluorescence, Alcian blue staining (at pH 2.5) for dermal mucin evaluation, and cytological examination.

Currently, no definitive therapeutic intervention for JLIS exists. Current management primarily consists of topical corticosteroids such as hydrocortisone, triamcinolone, and betamethasone. In more severe or refractory cases, systemic corticosteroids such as prednisone or antimalarial agents, including hydroxychloroquine, may be used.[4][22] Nonetheless, many patients choose not to pursue treatment for a benign condition, given the significant adverse effects associated with the main pharmacological options.[18] The initial line of treatment involves topical and intralesional corticosteroids.[22] In cases where photosensitivity is a concern, antimalarial medications may be more effective.[18] Additional therapies reported to be beneficial in case reports include tacrolimus, thalidomide, etretinate, methotrexate, oral auranofin, and proquazone.[17][23][24] Cosmetic camouflage, photoprotection, and surgical excision of small lesions may help conceal or eliminate the clinical manifestations of the condition. Less frequently used modalities include laser therapy, photodynamic therapy, and cryotherapy.

JLIS is among a group of histologically characterized conditions characterized by a lymphocytic infiltrate in the dermis. The conditions below, in conjunction with JLIS, are collectively referred to as the 5 L's.[8][20] Polymorphous light eruption: The presence of active lesions during the winter months or in regions with limited sun exposure may aid in differentiating JLIS from PLE. Discoid lupus erythematosus/lupus erythematosus tumidus: ANA, anti-Sm, and anti-dsDNA antibody testing can help differentiate JLIS from lupus erythematosus tumidus (LET). Due to its autoimmune etiology, LET exhibits a predominance in females. Compared to JLIS, LET demonstrates less truncal involvement. In addition, JLIS may demonstrate a higher proportion of B lymphocytes on biopsy.[7] Well-differentiated lymphocytic lymphoma: Lymphoma can involve the bone marrow, whereas JLIS is restricted to the skin. Lymphocytoma cutis: Lymphocytoma cutis typically demonstrates a polyclonal B-cell infiltrate.[25] Other differential diagnoses include: Cutaneous lymphoid hyperplasia [26] Granuloma annulare Granuloma faciale Gyrate erythema Erythematous mucinosis, which demonstrates positive Alcian blue staining for dermal mucin, whereas such staining is typically negative in JLIS [20] Rosacea [27]

Misdiagnosis JLIS may be misdiagnosed because it can resemble other dermatological conditions, particularly benign entities such as LET or PLE. JLIS may also be erroneously diagnosed as a malignancy, such as cutaneous lymphoma, which is a more serious condition requiring distinct therapeutic interventions. Ectropion Lesions surrounding the eyes may lead to ectropion, defined as the outward rotation of the lower eyelid. This condition can increase the risk of surgical failure in patients undergoing corrective procedures.[28][29] Adverse Effects of Treatment Therapeutic interventions for JLIS may entail adverse effects; for instance, the use of topical steroids may cause skin atrophy. Additionally, sunscreen use is recommended for patients with JLIS, as photosensitivity may be a trigger. Co-occurrence With Other Conditions A subset of patients may concurrently develop JLIS and PLE, along with other skin conditions such as psoriasis, or may experience alternating periods of both conditions.[24] Furthermore, patients with anti-HMGCR antibody-positive myopathy (HMGCR-IMNM) may present with multiple dermal manifestations, including JLIS, erythema multiforme, tinea versicolor, and cutaneous lymphoma.[11][12][19]

JLIS may benefit from a multidisciplinary approach. A dermatologist is recommended, and a plastic surgeon should be involved for cosmetic camouflage. If autoimmune testing yields positive results, consultation with a rheumatologist is advisable.

As the etiology remains unknown, there are no established preventive measures for JLIS. Nonetheless, given that photosensitivity may be a trigger for JLIS, patients are strongly advised to avoid sun exposure and to use effective photoprotection measures. Given the risk of ectropion, patients presenting with periorbital lesions should be subjected to close clinical monitoring. Finally, patients receiving medical therapy, including topical steroids and antimalarials, should attend regular follow-up appointments to enable early detection and management of adverse effects, such as skin atrophy.

The most critical aspects of managing JLIS are accurate diagnosis and treatment. Although JLIS is a rare, benign condition with a generally favorable prognosis, identification of a lesion requires careful evaluation to rule out more serious conditions, such as lymphoma.[5] Diagnosis begins with a dermatologist performing a biopsy, after which the tissue specimen is processed and analyzed by a pathologist, laboratory technologists, and supporting staff using immunohistologic techniques to confirm the condition.[25] Comprehensive care requires close collaboration among the patient, caregivers, and a multidisciplinary healthcare team. This team may include a rheumatologist if an autoimmune component is suspected. Moreover, when multiple family members are affected, it is advisable to counsel the entire family regarding the potential genetic predisposition to the disease.[10] Once JLIS is diagnosed, it is essential to educate the patient about available treatment options, taking into account risk factors such as photosensitivity, and to encourage shared decision-making in developing a treatment strategy tailored to their individual needs. Patients should also be informed that treatment may not be effective for all individuals and that outcomes can vary.[4][21] Depending on the treatment plan, consultation with a plastic surgeon may be warranted. Effective management of this condition requires clear communication among all members of the interprofessional team. For patients receiving medical therapy, close monitoring for adverse effects is recommended. Furthermore, patients diagnosed with JLIS should undergo regular skin examinations coordinated among the patient, caregivers, primary care providers, dermatologists, and other relevant healthcare professionals involved in patient care. Particular attention should be given to periorbital lesions, as these may progress to ectropion.[28]